Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Li, Ya Jun ^a   Li, Zhi Ming ^a   Xia, Yi ^a   Huang, Jia Jia ^a   Huang, Hui Qiang ^a   Xia, Zhong Jun ^a   Lin, Tong Yu ^a   Li, Su ^a   Cai, Xiu Yu ^a   Wu Xiao, Zhi Jun ^a   Jiang, Wen Qi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPOALBUMINEMIA; INTERNATIONAL PROGNOSTIC INDEX; KOREAN PROGNOSTIC INDEX; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REPUBLIC OF KOREA; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84878410620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064158     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. Lyon, France: International Agency for Research on Cancer.
2. Vose J, Armitage J, Weisenburger D, (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130.
3. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, et al. (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113: 3931-3937.
4. Lee J, Suh C, Park YH, Ko YH, Bang SM, et al. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24: 612-618.
5. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, et al. (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22: 149-155.
6. Chim CS, Ma SY, Au WY, Choy C, Lie AK, et al. (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103: 216-221.
7. You JY, Chi KH, Yang MH, Chen CC, Ho CH, et al. (2004) Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 15: 618-625.
8. Marnell L, Mold C, Du Clos TW, (2005) C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117: 104-111.
9. Nozoe T, Saeki H, Sugimachi K, (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182: 197-201.
10. McMillan DC, Canna K, McArdle CS, (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215-219.
11. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, et al. (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864.
12. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, et al. (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13: 1365-1370.
13. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444.
14. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R, (2010) Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 5: 988-992.
15. Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, et al. (2003) C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol 41: 21-25.
16. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, et al. (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31: 351-357.
17. Herishanu Y, Perry C, Braunstein R, Metser U, Goor O, et al. (2007) Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Haematol 79: 150-154.
18. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, et al. (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 33: 1039-1044.
19. Huang HH, Xiao F, Chen FY, Wang T, Li JM, et al. (2012) Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. Exp Ther Med 4: 475-480.
20. Allin KH, Nordestgaard BG, (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-170.
21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244.
22. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, et al. (2005) Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41: 1402-1408.
23. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
24. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
25. Ravishankaran P, Karunanithi R, (2011) Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9: 18.
26. Groblewska M, Mroczko B, Sosnowska D, Szmitkowski M, (2012) Interleukin 6 and C-reactive protein in esophageal cancer. Clin Chim Acta 413: 1583-1590.
27. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, et al. (2013) Inflammation-Mediated Genetic and Epigenetic Alterations Drive Cancer Development in the Neighboring Epithelium upon Stromal Abrogation of TGF-beta Signaling. PLoS Genet 9: e1003251.
28. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC, (2013) Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39: 89-96.
29. Yang J, Wezeman M, Zhang X, Lin P, Wang M, et al. (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12: 252-265.
30. Koenig W, Khuseyinova N, Baumert J, Meisinger C, (2008) Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 54: 335-342.
31. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG, (2010) C-reactive protein and all-cause mortality-the Copenhagen City Heart Study. Eur Heart J 31: 1624-1632.
32. Pieroni L, Bastard JP, Piton A, Khalil L, Hainque B, et al. (2003) Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 29: 133-138.
33. Pitsavos C, Chrysohoou C, Panagiotakos DB, Skoumas J, Zeimbekis A, et al. (2003) Association of leisure-time physical activity on inflammation markers (C-reactive protein, white cell blood count, serum amyloid A, and fibrinogen) in healthy subjects (from the ATTICA study). Am J Cardiol 91: 368-370.
34. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, et al. (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46: 464-469.
35. Delongui F, Kallaur AP, Oliveira SR, Bonametti AM, Grion CM, et al. (2013) Serum Levels of High Sensitive C Reactive Protein in Healthy Adults From Southern Brazil. J Clin Lab Anal.
36. Kim SJ, Kim BS, Choi CW, Choi J, Kim I, et al. (2007) Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 18: 1382-1387.
37. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC, (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94: 637-641.
38. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, et al. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633-2641.
39. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, et al. (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104: 726-734.